Literature DB >> 6252169

Management of severe systemic infections caused by multiple resistant organisms.

P M Shah, E B Helm, W Stille.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6252169     DOI： 10.1093/jac/6.suppl_a.269

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  [Therapy with cefotaxime-cefotaxime/ticarcillin for bronchopulmonary infections in patients under intensive care. (author's transl)].

Authors:  C D Schwigon
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 2.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

3.  The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.

Authors:  M Limbert; G Seibert; E Schrinner
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 4.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.